Two biotechs priced IPOs this past week and more joined the pipeline, along with a billion-dollar data center developer, an emerging markets fintech, and a dental treatment company. Autoimmune biotech TRex Bio (TRXB) priced at the low end to raise $117...read more
Retension Pharmaceuticals, a Phase 2b biotech developing an in-licensed treatment for hypertension, raised $45 million by offering 3.8 million shares at $12, within the $11 to $13 range. It had originally planned to offer 3.3 million shares. At pricing, the...read more
Retension Pharmaceuticals, a Phase 2b biotech developing an in-licensed treatment for hypertension, announced terms for its IPO on Monday. The Falls Church, VA-based company plans to raise $40 million by offering 3.3 million shares at a price range of $11 to...read more
Updated Monday, 10/5. The fourth quarter is off to a quiet start with two biotech IPOs currently scheduled for the week ahead. Autoimmune biotech TRex Bio (TRXB) plans to raise $125 million at a $453 million market cap. The company's Deep Biology platform...read more
US IPO Weekly Recap: Biotech IPOs keep flowing as data center developer DayOne joins the pipeline
Two biotechs priced IPOs this past week and more joined the pipeline, along with a billion-dollar data center developer, an emerging markets fintech, and a dental treatment company. Autoimmune biotech TRex Bio (TRXB) priced at the low end to raise $117...read more
Hypertension drug developer Retension Pharmaceuticals prices upsized IPO at $12 midpoint
Retension Pharmaceuticals, a Phase 2b biotech developing an in-licensed treatment for hypertension, raised $45 million by offering 3.8 million shares at $12, within the $11 to $13 range. It had originally planned to offer 3.3 million shares. At pricing, the...read more
Hypertension drug developer Retension Pharmaceuticals sets terms for $40 million IPO
Retension Pharmaceuticals, a Phase 2b biotech developing an in-licensed treatment for hypertension, announced terms for its IPO on Monday. The Falls Church, VA-based company plans to raise $40 million by offering 3.3 million shares at a price range of $11 to...read more
US IPO Week Ahead: Quiet start for the 4Q IPO market as Anthropic looms
Updated Monday, 10/5. The fourth quarter is off to a quiet start with two biotech IPOs currently scheduled for the week ahead. Autoimmune biotech TRex Bio (TRXB) plans to raise $125 million at a $453 million market cap. The company's Deep Biology platform...read more